Partnering & Licensing

Ocera is developing OCR-002 and AST-120
in varieties of indications with primary focus
on liver diseases.

Partnerships are available for our
pipeline in the following areas:

• OCR-002 for liver cirrhosis and liver failure: OCR-002 is in Phase 2 clinical trial addressing an unmet medical need to treat and prevent hepatic encephalopathy in patients with liver cirrhosis and acute liver failure.  Ocera will entertain partnering opportunities on OCR-002 to accelerate the development program, either regionally or on global basis. OCR-002 has an orphan drug designation and fast track in the U.S., and will be prescribed by liver disease specialists who treat liver cirrhosis in both hospital and outpatient basis.     
• AST-120 for Irritable Bowel Syndrome: Ocera will collaborate with partner(s) to move AST-120 through late stage development. The product is Phase 2b ready in the U.S., and is under CE mark evaluation in the EU. AST-120 has a substantial safety record which is essential for the treatment of chronic symptoms such as IBS. The product also has fast track designation in the U.S.

Why partner with us?

for more information about partnering with Ocera, contact:

Akiko Shibata VP, Business Operations ashibata@ocerainc.com

• Clinical Development and Regulatory Expertise:  Ocera is structured to support multiple clinical development programs and regulatory filings.  Combined, the team has over 100 years of development expertise and has launched products in multiple therapeutic areas. 
• Funding:  Ocera has raised $62 million and has a team of dedicated life science investors with a proven track record and funding capability.
• Action Oriented and Deliverable Focused:  Ocera prides itself for being a dynamic organization that focuses on cost-effective, high quality clinical development programs that create significant value for our partners. Our business model is flexible and can adapt to our partners’ needs, whether corporate or academic.

Current Partners:

Kureha Corporation: Kureha Corporation, located in Tokyo, Japan is a leading diversified chemical products developer and manufacturer that applies its technological expertise to create novel products in pharmaceutical, agrochemical, and packaging material areas. Daiichi-Sankyo markets AST-120 in Japan for chronic kidney disease patients to delay the time to dialysis. Ocera in-licensed AST-120 from Kureha in 2005. Ocera has the rights to AST-120 for liver and gastrointestinal diseases globally except for Asian countries (Japan, China, Korea, Taiwan, Philippines and India).		University College London Business: UCL Business PLC (UCLB) is a wholly owned subsidiary of University College London (UCL). Through partnering and collaborations, UCLB is responsible for commercializing research across all disciplines generated from UCL and associated organizations. Ocera licensed UCL-L1V and assets and technologies around the compound. The Ocera designation of UCL-L1V is OCR-002. Clinical studies will be initiated by UCL under a grant from the UK’s Medical Research Council in 2009 for AHE in cirrhosis and acute liver failure. Ocera plans to file an IND for OCR-002 in 2010 followed by trials in acute hepatic encephalopathy in patients with liver cirrhosis and in acute liver failure.